
==== Front
Turk Patoloji Derg
Turk Patoloji Derg
Turk Patoloji Derg
Turkish Journal of Pathology
1018-5615
1309-5730
1018-5615
Federation of Turkish Pathology Societies Ankara, Turkey

39171856
10.5146/tjpath.2024.13681
Review
Hot Trends in Pheochromocytoma and Paraganglioma: Are We Getting Closer to Personalized Dynamic Prognostication?
Juhlin C. Christofer
Mete Ozgur *
Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden
Department of Pathology, University Health Network, Toronto, ON, Canada; Endocrine Oncology Site, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
* E-mail: ozgur.mete2@uhn.ca
Concept: CCJ, OM, Design: CCJ, OM, Supervision: Not applicable, Materials: Not applicable, Data collection and/or processing: Not applicable, Analysis and/or interpretation: Not applicable, Literature search: CCJ, OM, Writing: CCJ, OM, Approval: CCJ, OM.

2024
02 9 2024
40 3 143148
09 8 2022
09 8 2023
Copyright © 2024 The Author(s).
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ This is an open-access article published by Federation of Turkish Pathology Societies under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.
Pheochromocytoma and abdominal paraganglioma (PPGL) are rare catecholamine-producing, keratin-negative, non-epithelial neuroendocrine neoplasms characterized by a unique association with syndromic diseases caused by constitutional mutations in a wide range of susceptibility genes. While PPGLs are recognized for their malignant potential, the risk of metastatic disease varies depending on several clinical, histological, and genetic factors. Accurate diagnosis and prognosis of these tumors require a multidisciplinary approach, integrating insights from various medical specialties. Pathologists play a crucial role in this complex task, as numerous morphological, immunohistochemical, and genetic findings can be linked to worse outcomes. Therefore, it is vital to stay informed about the latest advancements in PPGL pathology. This brief review provides an overview of the challenges associated with PPGLs and highlights the most recent developments in tumor prognostication.

Pheochromocytoma
Paraganglioma
Pathology
Diagnostic
Prognostic
Review
==== Body
pmcPheochromocytomas and paragangliomas (PPGL) are non-epithelial neuroendocrine neoplasms of the paraganglia with unique hormonal, hereditary, and histological characteristics (1,2). Diagnosing these enigmatic neoplasms requires an integrated approach, including thorough patient history, symptomatology, biochemical analysis, radiology, histopathology, and genetic analysis, involving multiple specialties (3,4). The diagnosis is usually suggested following the identification of an adrenal or extra-adrenal mass on CT scan, followed by hormonal work-up identifying elevated levels of catecholamines (3-metoxytyramine/dopamine, normetanephrine/norepinephrine, and metanephrine/epinephrine) (5). From a histopathological perspective, PPGLs present challenges for surgical pathologists, as these tumors may mimic other lesions with similar growth patterns including epithelial neuroendocrine neoplasms of various sites (6,7). Therefore, care must be taken to verify the tumor using immunohistochemistry (1,8,9). By definition, PPGLs are keratin-negative, non-epithelial neuroendocrine neoplasms that show immunoreactivity to INSM1, chromogranin A and synaptophysin. They are usually positive for GATA3, and subsets of tumors may exhibit S100 nuclear and cytoplasmic expression. Moreover, recent data suggest that PHOX2B and Hand2 are reliable markers to distinguish PPGLs from epithelial neuroendocrine neoplasms (10,11). Since PPGLs are highly heritable neuroendocrine neoplasms, the standard care also includes the assessment of underlying germline susceptibility (1,12). While multifocality and some morphological findings can be used to support underlying germline susceptibility, immunohistochemical analysis related to pathogenic biomarkers can guide clinical genetics (e.g., SDHB, CAIX, alpha-inhibin, 2-SC, FH) (1). Moreover, in some circumstances, molecular immunohistochemistry, particularly SDHB or FH/2-SC can help to narrow down the pathogenicity of a variant of uncertain significance (VUS) (1,13).

It is now well-established that all PPGLs are malignant neoplasms with metastatic potential, but estimating the risk of metastasis is a difficult challenge. While multiparameter scoring systems are no longer parts of the routine pathology practice, how to properly estimate the risk of metastatic dissemination is a growing area of interest for multidisciplinary teams in endocrine oncology. The two most established histological algorithms for predicting aggressive biological behavior have limitations in reproducibility and positive predictive values (14). While these algorithms can potentially help to rule out tumors that are not at risk of spreading, they may also miss some tumors that subsequently metastasize. Even so, some adverse histological parameters seem important to recognize, such as the presence of angioinvasion, tumor necrosis, the overall growth pattern, cellularity, reduced to absent intratumoral sustentacular cell network, margin status and the extent of the tumor. As a result, modern endocrine oncology has now transitioned to a personalized dynamic risk stratification based on clinical/biochemical, pathological and molecular risk factors (Figure 1) (1).

Figure 1 Clinical, histological, immunohistochemical and molecular approaches to identify pheochromocytoma and paraganglioma (PPGL) at risk of metastatic dissemination.

NE: Norepinephrine, D: Dopamine, TCA: Tricarboxylic acid cycle. Created using BioRender.com.

The underlying genetics can provide important clues with regards to risk of disease dissemination, as mutations in genes encoding various enzymes within the pseudo-hypoxia pathway regulation, especially tricarboxylic acid (TCA) cycle associated proteins, correlate to metastatic potential (9,15). Mutations in subunits of the succinate dehydrogenase (SDH) gene family, especially SDHB, SDHC, and SDHD, are notably associated with an increased risk of metastatic dissemination, making genetic analysis of prognostic value. Additionally, SDHB immunohistochemistry is a valuable tool for triaging cases for genetic screening, as SDHB immunoreactivity is lost in virtually all PPGLs driven by pathogenic SDHB, SDHC and SDHD variants (Figure 2). Similarly, alpha-inhibin immunohistochemistry has been shown to identify PPGLs with mutations in various genes within the pseudo-hypoxic pathway, not restricted to SDHx gene mutations (16). CAIX immunostaining may also identify VHL-mutated tumors, which carry a small but non-negligible risk of dissemination (17). Subsets of biologically aggressive PPGLs are associated with aberrant Wnt signaling, and these tumors often carry somatic MAML3 gene fusions or CSDE1 mutations (18). PPGLs in this cluster are more often metastatic than traditional PPGLs driven by kinase-related mutations.

Figure 2 SDHB mutated pheochromocytomas and paragangliomas (PPGLs) have an increased risk of metastatic spread. A) Hematoxylineosin stained section of an SDHB mutated PPGL, displaying the characteristic eosinophilic cytoplasm with occasional vacuolization. B) Venous (vascular) invasion is often seen, a recognized adverse histological parameter. C) SDH deficiency on SDHB immunohistochemistry is characterized by loss of cytoplasmic granular reactivity in the tumor cells, with adjacent stromal and endothelial cells as internal positive control D) Positive SDHB staining in a PPGL with wildtype SDHx genes.

Although not coupled to adverse prognosis, the pathologist may facilitate detection of other gene mutations that may lead to the detection of hereditary disease. For example, rare cases of MAX mutated or MAX rearranged PPGLs typically exhibit loss of MAX protein expression, adding another potential tool to the diagnostic workup of these lesions. In contrast, there are no good commercial antibodies that can distinguish NF1 and RET-mutant tumors (19,20). The assessment of non-tumorous parenchyma is critical since adrenal medullary hyperplasia is a sign of germline pathogenic variants (e.g., RET, MAX, NF1, TMEM127, SDHB) (1,21). The presence of composite tumor elements should raise the genetic screening of RET, NF1, and MAX-driven pathogenesis (1).

Years of focused PPGL research have also provided pathologists with better tools to assess the metastatic potential of these tumors, and many of the advances target proliferation markers or transcription factors associated with metastatic cases. The correlation between rapidly proliferating tumors and metastatic risk is well-known, and studies on the Ki-67 proliferation index in PPGL have shown higher proliferative activity in metastatic cases (9,22). Consequently, the two most established histologic algorithms for assessing proliferation risk in PPGL incorporate mitotic count or Ki-67 labeling index as weighted parameters (Figure 3). Similarly, the topoisomerase 2A (TOP2A) expression, a protein involved in chromosomal condensation and segregation during mitosis, is also increased in PPGLs with poor outcome (23). Overall, the proliferative activity seems to be an important factor when establishing the risk of dissemination, similar to other endocrine and neuroendocrine neoplasms.

Figure 3 Immunohistochemistry in the triage of biologically aggressive aggressive pheochromocytomas and paragangliomas (PPGLs). A) ATRX immunohistochemistry can be used to identify underlying somatic ATRX gene mutations, a genetic event coupled to worse outcome. B) The Ki-67 labeling index is a reliable method to identify PPGLs with an increased

Moreover, somatic mutations in chromatin-remodeling and histone-modifying genes such as ATRX, SETD2 and KMT2D have been reported in metastatic PPGL (24,25). TERT gene aberrations, including promoter mutations, gene rearrangements, copy number gains, and aberrant methylation, have also been suggested as adverse molecular events (26–28). A recent study identified high mutational burden, microsatellite instability (MSI), increased somatic copy-number alterations, and ATRX/TERT aberrations as closely associated with metastatic disease (Figure 3) (29). Although many clinically accredited next-generation sequencing panels include ATRX and the TERT promoter, the combination of mutational burden, MSI, and gene copy number analyses is not yet used in clinical routine practice. However, the same study also identified CDK1 expression as highly associated with the aforementioned genetic profile in metastatic PPGL (29). Although promising from a clinical screening perspective, this observation needs to be verified by independent investigators.

Another area of increased focus in PPGL research is metabolomics and immune signatures (30,31). Mutations in TCA cycle components inhibit the metabolic pathway and lead to the accumulation of specific metabolites, including succinate, fumarate, and alpha-ketoglutarate, which can be oncogenic. Measuring these so-called onco-metabolites may have clinical value. Studies have shown that analyzing metabolite profiles can improve PPGL risk assessment, although the methodology remains expensive and rather intricate.

At the clinical and pathological level, distinction of multifocal primary disease from metastatic disease is an important challenge that requires knowledge of the distribution of the autonomous nervous system (1,2). As a result, tumors identified in liver and lungs are not always a sign of metastatic disease. The role of sustentacular cells in the distinction of metastatic disease from primary PPGL has also been evolved (32).

Even though histological, immunohistochemical, and molecular advances have increased our understanding of which PPGLs will subsequently disseminate, one must not overlook baseline clinical characteristics, which are important clues to identifying cases that will metastasize. For example, TCA-related PPGLs (with their inherent risk of dissemination) are overrepresented among cases with norepinephrine and/or dopamine production. Other established risk factors include large tumor size, older age at surgery, and male gender. These data are supported by recent machine learning models using artificial intelligence and clinical data from PPGL patients. These models showed that an algorithm considering plasma 3-methoxytyramine, metanephrine, normetanephrine, age, gender, previous history of PPGL, location and size of primary tumors, and the presence of multifocal disease was an efficient tool to predict metastatic disease (33). Thus, an integrated approach using clinical, pathological, and genetic variables is ultimately required to assess PPGL patients, and requiring well-established cooperation between radiologists, oncologists, geneticists, surgeons and pathologists (Figure 1).

Conflict of Interest

The authors have no conflicts of interest to report.
==== Refs
Mete Ozgur , Asa Sylvia L. , Gill Anthony J. , Kimura Noriko , Krijger Ronald R. de , Tischler Arthur Endocr Pathol Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas 03 2022
33 90 114 10.1007/s12022-022-09704-6 35285002
Juhlin Carl Christofer , Mete Ozgur Adv Anat Pathol Advances in Adrenal and Extra-adrenal Paraganglioma: Practical Synopsis for Pathologists 01 2023
30 47 57 10.1097/PAP.0000000000000365
Asa Sylvia L. , Uccella Silvia , Tischler Arthur Endocr Pathol The Unique Importance of Differentiation and Function in Endocrine Neoplasia 12 2023
34 382 392 10.1007/s12022-023-09762-4
Ezzat Shereen , Herder Wouter W. de , Volante Marco , Grossman Ashley Endocr Pathol The Driver Role of Pathologists in Endocrine Oncology: What Clinicians Seek in Pathology Reports 12 2023
34 437 454 10.1007/s12022-023-09768-y
Calissendorff Jan , Juhlin Carl Christofer , Bancos Irina , Falhammar Henrik Cancers (Basel) Pheochromocytomas and Abdominal Paragangliomas: A Practical Guidance 02 2022
14 917 917 10.3390/cancers14040917
Vanoli Alessandro , Messina Alessia , Gallotti Anna , Fugazzola Paola , Adsay Volkan Endocr Pathol Well-Differentiated Neuroendocrine Tumor of the Gallbladder with Paraganglioma-Like Features: a Potential Mimicker of Gallbladder Paraganglioma 09 2023
34 358 360 10.1007/s12022-023-09784-y 37599339
Jung Chan Kwon , Agarwal Shipra , Hang Jen-Fan , Lim Dong-Jun , Bychkov Andrey , Mete Ozgur Endocr Pathol Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma 03 2023
34 1 22 10.1007/s12022-023-09753-5 36890425
Rindi Guido , Mete Ozgur , Uccella Silvia , Basturk Olca , La Rosa Stefano , Brosens Lodewijk A. A. , Ezzat Shereen , Herder Wouter W. de , Klimstra David S. , Papotti Mauro , Asa Sylvia L. Endocr Pathol Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms 03 2022
33 115 154 10.1007/s12022-022-09708-2 35294740
Juhlin C. Christofer Endocr Pathol Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry 06 2021
32 228 244 10.1007/s12022-021-09675-0 33768452
Miyauchi Minami , Akashi Takumi , Furukawa Asuka , Uchida Keisuke , Tamura Tomoki , Ando Noboru , Kirimura Susumu , Shintaku Hiroshi , Yamamoto Kurara , Ito Takashi , Miura Keiko , Kayamori Kou , Ariizumi Yosuke , Asakage Takahiro , Kudo Atsushi , Tanabe Minoru , Fujii Yasuhisa , Ishibashi Hironori , Okubo Kenichi , Murakami Masanori , Yamada Tetsuya , Takemoto Akira , Bae Yuan , Eishi Yoshinobu , Ohashi Kenichi Endocr Pathol PHOX2B is a Sensitive and Specific Marker for the Histopathological Diagnosis of Pheochromocytoma and Paraganglioma 12 2022
33 506 518 10.1007/s12022-022-09730-4
Soukup Jiri , Manethova Monika , Stejskal Vaclav , Novakova Marie , Duskova Jaroslava , Hornychova Helena , Hacova Maria , Staniczkova-Zambo Iva , Zelinka Tomas , Kosak Mikulas , Cesak Tomas , Netuka David , Ryska Ales , Gabalec Filip Endocr Pathol Hand2 Immunohistochemistry in the Diagnosis of Paragangliomas and Other Neuroendocrine Neoplasms 03 2024
35 14 24 10.1007/s12022-024-09803-6 38416360
Nosé Vania , Gill Anthony , Teijeiro José Manuel Cameselle , Perren Aurel , Erickson Lori Endocr Pathol Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes 03 2022
33 197 227 10.1007/s12022-022-09705-5 35285003
Papathomas Thomas G. , Oudijk Lindsey , Persu Alexandre , Gill Anthony J. , Nederveen Francien van , Tischler Arthur S. , Tissier Frédérique , Volante Marco , Matias-Guiu Xavier , Smid Marcel , Favier Judith , Rapizzi Elena , Libe Rosella , Currás-Freixes Maria , Aydin Selda , Huynh Thanh , Lichtenauer Urs , Berkel Anouk van , Canu Letizia , Domingues Rita , Clifton-Bligh Roderick J. , Bialas Magdalena , Vikkula Miikka , Baretton Gustavo , Papotti Mauro , Nesi Gabriella , Badoual Cécile , Pacak Karel , Eisenhofer Graeme , Timmers Henri J. , Beuschlein Felix , Bertherat Jérôme , Mannelli Massimo , Robledo Mercedes , Gimenez-Roqueplo Anne-Paule , Dinjens Winand Nm , Korpershoek Esther , Krijger Ronald R. de Mod Pathol SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T) 06 2015
28 807 821 10.1038/modpathol.2015.41 25720320
Stenman Adam , Zedenius Jan , Juhlin Carl Christofer Cancers (Basel) The Value of Histological Algorithms to Predict the Malignancy Potential of Pheochromocytomas and Abdominal Paragangliomas-A Meta-Analysis and Systematic Review of the Literature 02 2019
11 225 225 10.3390/cancers11020225
Crona Joakim , Lamarca Angela , Ghosal Suman , Welin Staffan , Skogseid Britt , Pacak Karel Endocr Relat Cancer Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis 05 2019
26 539 550 10.1530/ERC-19-0024 30893643
Mete Ozgur , Pakbaz Sara , Lerario Antonio M. , Giordano Thomas J. , Asa Sylvia L. Am J Surg Pathol Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas 09 2021
45 1264 1273 10.1097/PAS.0000000000001715 33826547
Favier Judith , Meatchi Tchao , Robidel Estelle , Badoual Cécile , Sibony Mathilde , Nguyen An Thach , Gimenez-Roqueplo Anne-Paule , Burnichon Nelly Mod Pathol Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study 01 2020
33 57 64 10.1038/s41379-019-0343-4
Fishbein Lauren , Leshchiner Ignaty , Walter Vonn , Danilova Ludmila , Robertson A. Gordon , Johnson Amy R. , Lichtenberg Tara M. , Murray Bradley A. , Ghayee Hans K. , Else Tobias , Ling Shiyun , Jefferys Stuart R. , Cubas Aguirre A. de , Wenz Brandon , Korpershoek Esther , Amelio Antonio L. , Makowski Liza , Rathmell W. Kimryn , Gimenez-Roqueplo Anne-Paule , Giordano Thomas J. , Asa Sylvia L. , Tischler Arthur S. , Cancer Genome Atlas Research Network, Pacak Karel , Nathanson Katherine L. , Wilkerson Matthew D. Cancer Cell Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma 02 2017
31 181 193 10.1016/j.ccell.2017.01.001
Stenman Adam , Svahn Fredrika , Welander Jenny , Gustavson Boel , Söderkvist Peter , Gimm Oliver , Juhlin C. Christofer Endocr Pathol Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma 03 2015
26 9 14 10.1007/s12022-014-9348-1 25403449
Powers James F. , Brachold Jaime M. , Tischler Arthur S. Endocr Pathol Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma 2003
14 351 361 10.1385/ep:14:4:351 14739491
Tischler Arthur S. , LiVolsi Virginia A. , Asa Sylvia L. Endocr Pathol Insights Obtained from the Nontumorous Glandular Tissue in Patients with Endocrine Tumors 12 2023
34 393 405 10.1007/s12022-023-09759-z
La Rosa Stefano Endocr Pathol Diagnostic, Prognostic, and Predictive Role of Ki67 Proliferative Index in Neuroendocrine and Endocrine Neoplasms: Past, Present, and Future 03 2023
34 79 97 10.1007/s12022-023-09755-3 36797453
Solhusløkk Höse Karolina , Stenman Adam , Svahn Fredrika , Larsson Catharina , Juhlin C. Christofer Endocr Pathol TOP2A Expression in Pheochromocytoma and Abdominal Paraganglioma: a Marker of Poor Clinical Outcome? 03 2023
34 129 141 10.1007/s12022-022-09746-w 36656469
Job Sylvie , Draskovic Irena , Burnichon Nelly , Buffet Alexandre , Cros Jérôme , Lépine Charles , Venisse Annabelle , Robidel Estelle , Verkarre Virginie , Meatchi Tchao , Sibony Mathilde , Amar Laurence , Bertherat Jérôme , Reyniès Aurélien de , Londoño-Vallejo Arturo , Favier Judith , Castro-Vega Luis Jaime , Gimenez-Roqueplo Anne-Paule Clin Cancer Res Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma 01 2019
25 760 770 10.1158/1078-0432.CCR-18-0139
Juhlin C. Christofer , Stenman Adam , Haglund Felix , Clark Victoria E. , Brown Taylor C. , Baranoski Jacob , Bilguvar Kaya , Goh Gerald , Welander Jenny , Svahn Fredrika , Rubinstein Jill C. , Caramuta Stefano , Yasuno Katsuhito , Günel Murat , Bäckdahl Martin , Gimm Oliver , Söderkvist Peter , Prasad Manju L. , Korah Reju , Lifton Richard P. , Carling Tobias Genes Chromosomes Cancer Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene 09 2015
54 542 554 10.1002/gcc.22267 26032282
Dwight Trisha , Flynn Aidan , Amarasinghe Kaushalya , Benn Diana E. , Lupat Richard , Li Jason , Cameron Daniel L. , Hogg Annette , Balachander Shiva , Candiloro Ida L. M. , Wong Stephen Q. , Robinson Bruce G. , Papenfuss Anthony T. , Gill Anthony J. , Dobrovic Alexander , Hicks Rodney J. , Clifton-Bligh Roderick J. , Tothill Richard W. Endocr Relat Cancer TERT structural rearrangements in metastatic pheochromocytomas 01 2018
25 1 9 10.1530/ERC-17-0306
Liu Tiantian , Brown Taylor C. , Juhlin C. Christofer , Andreasson Adam , Wang Na , Bäckdahl Martin , Healy James M. , Prasad Manju L. , Korah Reju , Carling Tobias , Xu Dawei , Larsson Catharina Endocr Relat Cancer The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors 06 2014
21 427 434 10.1530/ERC-14-0016 24803525
Svahn Fredrika , Juhlin C. Christofer , Paulsson Johan O. , Fotouhi Omid , Zedenius Jan , Larsson Catharina , Stenman Adam Clin Endocrinol (Oxf) Telomerase reverse transcriptase promoter hypermethylation is associated with metastatic disease in abdominal paraganglioma 02 2018
88 343 345 10.1111/cen.13513
Calsina Bruna , Piñeiro-Yáñez Elena , Martínez-Montes Ángel M. , Caleiras Eduardo , Fernández-Sanromán Ángel , Monteagudo María , Torres-Pérez Rafael , Fustero-Torre Coral , Pulgarín-Alfaro Marta , Gil Eduardo , Letón Rocío , Jiménez Scherezade , García-Martín Santiago , Martin Maria Carmen , Roldán-Romero Juan María , Lanillos Javier , Mellid Sara , Santos María , Díaz-Talavera Alberto , Rubio Ángeles , González Patricia , Hernando Barbara , Bechmann Nicole , Dona Margo , Calatayud María , Guadalix Sonsoles , Álvarez-Escolá Cristina , Regojo Rita M. , Aller Javier , Del Olmo-Garcia Maria Isabel , López-Fernández Adrià , Fliedner Stephanie M. J. , Rapizzi Elena , Fassnacht Martin , Beuschlein Felix , Quinkler Marcus , Toledo Rodrigo A. , Mannelli Massimo , Timmers Henri J. , Eisenhofer Graeme , Rodríguez-Perales Sandra , Domínguez Orlando , Macintyre Geoffrey , Currás-Freixes Maria , Rodríguez-Antona Cristina , Cascón Alberto , Leandro-García Luis J. , Montero-Conde Cristina , Roncador Giovanna , García-García Juan Fernando , Pacak Karel , Al-Shahrour Fátima , Robledo Mercedes Nat Commun Genomic and immune landscape Of metastatic pheochromocytoma and paraganglioma 02 2023
14 1122 1122 10.1038/s41467-023-36769-6
Richter Susan , Garrett Timothy J , Bechmann Nicole , Clifton-Bligh Roderick J , Ghayee Hans K Endocrine-Related Cancer Metabolomics in paraganglioma: applications and perspectives from genetics to therapy 03 2023
30 e220376 e220376 10.1530/ERC-22-0376 36897220
Ghosal Suman , Hadrava Vanova Katerina , Uher Ondrej , Das Shaoli , Patel Mayank , Meuter Leah , Huynh Thanh-Truc , Jha Abhishek , Talvacchio Sara , Knue Marianne , Prodanov Tamara , Zeiger Martha A. , Nilubol Naris , Taieb David , Crona Joakim , Shankavaram Uma T. , Pacak Karel Endocrine Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis 01 2023
79 171 179 10.1007/s12020-022-03218-1
Powers James F. , Tischler Arthur S. Endocr Pathol Immunohistochemical Staining for SOX10 and SDHB in SDH-Deficient Paragangliomas Indicates that Sustentacular Cells Are Not Neoplastic 09 2020
31 307 309 10.1007/s12022-020-09633-2 32562155
Pamporaki Christina , Berends Annika M. A. , Filippatos Angelos , Prodanov Tamara , Meuter Leah , Prejbisz Alexander , Beuschlein Felix , Fassnacht Martin , Timmers Henri J. L. M. , Nölting Svenja , Abhyankar Kaushik , Constantinescu Georgiana , Kunath Carola , Haas Robbert J. de , Wang Katharina , Remde Hanna , Bornstein Stefan R. , Januszewicz Andrzeij , Robledo Mercedes , Lenders Jacques W. M. , Kerstens Michiel N. , Pacak Karel , Eisenhofer Graeme Lancet Digit Health Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort 09 2023
5 e551 e559 10.1016/S2589-7500(23)00094-8 37474439
